The Simple Truth

Why these three exist, in plain English.

A GLP drug exists to make you stop eating so much. Tirzepatide and retatrutide copy gut hormones your body releases after a meal. Those hormones tell your brain you're full and tell your pancreas to handle the incoming sugar. Copy them well enough and appetite drops hard. That's why these drugs work, and it's the whole story — they are appetite and energy-balance drugs, not fat-targeting drugs.

AOD-9604 exists because someone tried to keep the fat-burning half of growth hormone and throw away the rest. Growth hormone releases fat from fat cells, but it also raises blood sugar and makes tissue grow — side effects nobody wanted. AOD-9604 is a small piece clipped off the end of the growth hormone molecule, chosen because in animals that piece seemed to burn fat without the sugar problem. It exists as an attempt at a cleaner tool, not as a stronger one.

MOTS-c exists because your mitochondria turned out to be talking. Mitochondria were taught as the cell's power plants, full stop. In 2015 researchers found the mitochondria's own DNA codes for a tiny peptide that travels out and gives instructions to the rest of the cell about how to handle fuel. Your body makes less of it as you age. MOTS-c exists as a way to study that conversation — it's a metabolic signal, not a weight-loss drug.

So: one suppresses appetite, one tries to mobilise fat, one tunes how cells burn fuel. That's the honest reason anyone looks at the three together — and the rest of this article is about how much of that reasoning the evidence actually supports.

Key Takeaways
  • The three compounds act on genuinely different layers: appetite and energy balance (GLP), fat mobilisation (AOD-9604), and cellular fuel handling (MOTS-c).
  • Incretin trial data is strong and human. SURMOUNT-1 and the retatrutide phase 2 are large randomised trials published in NEJM.
  • AOD-9604's supportive data is rodent, from 2001. Its large human trial — OPTIONS, 502 randomised — found no significant difference on the primary weight-loss endpoint.
  • MOTS-c is preclinical. The 2015 discovery paper and the 2021 exercise work are mouse studies; human data is observational.
  • The mechanistically defensible reason to study the combination is body composition — incretin-driven weight loss includes substantial fat-free mass.
  • No published trial has tested this combination in humans. The rationale is mechanistic, not demonstrated.

Three Different Layers

Most peptide "stacks" discussed in forums are really the same mechanism twice — two growth hormone secretagogues, or two healing peptides — which buys redundancy rather than coverage. This combination is unusual because the three compounds genuinely do not overlap.

Work upward from the cell. MOTS-c operates inside the cell, on how mitochondria and the nucleus coordinate fuel use. AOD-9604 operates at the fat cell, on whether stored triglyceride is released. The incretin agonists operate at the level of the whole organism, on appetite, gastric emptying and insulin secretion.

That separation is the entire argument for looking at them together. It is also, as we'll get to, where the argument stops — because "non-overlapping mechanisms" is a hypothesis about a combination, not evidence for one.

AOD-9604: The Lipolytic Fragment

AOD-9604 is a modified fragment of human growth hormone, corresponding to the C-terminal region around residues 177–191. The idea behind it is genuinely elegant: growth hormone's effects split roughly into anabolic actions (tissue growth, IGF-1 production, and the insulin resistance that comes with them) and metabolic actions (fat breakdown). If those functions live in different parts of the molecule, you could keep one and discard the other.

In mice, that is close to what happened. Chronic treatment in obese mice increased fat oxidation and reduced body weight [1], and work published the same year reported effects on lipid metabolism in obese and β3-adrenergic-receptor knockout mice without the glucose intolerance that full-length growth hormone produces [2]. The β3-knockout detail mattered, because it argued the effect wasn't simply running through the classic adrenergic fat-burning pathway.

Here is the part that gets left out of most summaries, and it is not that the human data is missing. It exists, and it is unfavourable. The FDA's 2024 Pharmacy Compounding Advisory Committee briefing describes the OPTIONS study: 536 adults with obesity enrolled, 502 randomised, double-blind and placebo-controlled, oral AOD-9604 against placebo alongside a supervised diet and exercise programme over 24 weeks. FDA reports no significant difference in the primary weight-loss endpoint. The briefing's overall conclusion was that the available evidence did not support effectiveness for obesity [11].

That is a considerably more important fact than "the mouse data is old," and it cuts directly against the reason anyone would put AOD-9604 in a fat-loss stack. It is also frequently answered with a route argument — the trial was oral, so injection must work better. That is a new hypothesis, not a finding. An untested route cannot inherit the animal results while being excused from the human ones.

So AOD-9604 should be read as a mechanistically interesting fragment whose central human test did not confirm the proposition it is sold on. Our AOD-9604 guide works through the regulatory assessment in detail.

MOTS-c: The Mitochondrial Signal

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA — which is what made its 2015 description notable rather than incremental. The discovery paper showed it activates AMPK, improves insulin sensitivity and reduces diet-induced obesity in mice [3]. Mitochondria, it turned out, send instructions outward.

The follow-up work is where it becomes relevant to a stack. A 2021 study characterised MOTS-c as exercise-induced and tied it to age-dependent physical decline and muscle homeostasis [4], and more recent work reports improvements in intrinsic muscle mitochondrial bioenergetic health through a PGC-1α/AMPK-associated pathway [5]. The through-line is skeletal muscle quality, not body weight.

That is a different target from either of the other two compounds, and it is the reason MOTS-c appears in this discussion at all. Nobody studying MOTS-c seriously describes it as a weight-loss agent. Our MOTS-c guide and the mitochondrial peptides deep dive cover the biology further.

The honest framing: MOTS-c has the most interesting mechanism of the three and the least human evidence. Human studies to date are largely observational — measuring circulating MOTS-c and correlating it with fitness, age or metabolic disease — not interventional.

The GLP Layer

This is the layer where the evidence is not in question. Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced mean weight reductions of roughly 15–21% across doses over 72 weeks in SURMOUNT-1 [6], and outperformed semaglutide on glycaemic control in SURPASS-2 [7]. Retatrutide, which adds glucagon receptor agonism for triple activity, reported mean reductions around 24% at 48 weeks in its phase 2 trial [8].

Those are large, randomised, peer-reviewed human trials. In a discussion where two of three compounds rest on mouse data, the incretin layer is carrying the actual clinical weight — and it is worth being explicit that any combination's observed results would largely be the GLP's results.

Compound-level detail is in our tirzepatide and retatrutide guides, and the class mechanism is covered in GLP-1 receptor agonists explained.

Why Body Composition Is the Real Question

If you frame the stack as "more weight loss," it is hard to defend. The GLP alone produces more weight loss than anything else in the conversation, and adding compounds with no human efficacy data to a drug with excellent human efficacy data is not obviously additive.

Framed around composition, the reasoning gets considerably better. A 2026 systematic review of incretin-based and non-pharmacologic weight loss found that body composition changes with incretin therapy include meaningful reductions in fat-free mass alongside fat mass [9] — a pattern consistent with earlier analyses of weight-loss composition in this drug class. The clinical concern that follows has been raised directly in the context of older adults and sarcopenic obesity [10].

That reframes the question usefully. The problem incretin monotherapy does not solve is what the lost mass is made of. And that is precisely the axis MOTS-c's literature sits on — skeletal muscle mitochondrial quality and age-related physical decline — while AOD-9604's rationale is shifting the fuel source toward fat oxidation specifically.

None of that is a demonstrated result. It is a coherent hypothesis about why non-overlapping mechanisms might matter here more than in a typical stack, and it is the version of the argument that survives contact with the literature.

What Circulates, and Where the Numbers Come From

Search for this combination and you will find a fairly consistent picture: a weekly GLP, AOD-9604 daily in the morning before eating, and MOTS-c two or three times a week, often placed around training days. The commonly repeated figures sit around 250–300 mcg for AOD-9604 and roughly 5–10 mg weekly for MOTS-c.

Peptide Mag does not publish protocols, and this is not one. But it is worth examining where that convention came from, because the provenance is the useful part — and it is not what most readers assume.

The reasoning is internally coherent. Fasted morning dosing for AOD-9604 follows from insulin suppressing fat release, so you dose when insulin is lowest. Placing MOTS-c near training follows from the exercise-mimetic framing — pair it with the stimulus it is said to mimic. The weekly GLP sits underneath as the appetite layer. Nothing about that logic is stupid. It is also not evidence.

The AOD-9604 numbers do not come from the human trial. This is the detail that matters most and is almost never stated. The large human study was oral, and it did not meet its primary endpoint. The circulating figures describe subcutaneous injection — a different route, with no equivalent trial behind it. So the convention is not a dose carried over from a successful human study; it is a number attached to a route the human programme did not validate, for a proposition the human programme failed to confirm.

The MOTS-c numbers have no human provenance at all. No published trial has administered MOTS-c to people. The figures in circulation are scaled from rodent experiments, and interspecies dose scaling for peptides is unreliable enough that the spread between sources is wide. A separately named investigational product, CB4211, is sometimes cited as if it were native MOTS-c; it is not the same intervention, a distinction our MOTS-c guide sets out.

What that leaves. The convention is stable because it has been repeated, not because it was tested. One component's numbers point at an unvalidated route for a failed proposition; another's are extrapolated from mice; only the GLP's schedule rests on trials that actually ran. Anyone presenting the three together as a protocol is describing a practice, not reporting a result — and a reader is entitled to know which of those they are being handed.

Honest Limitations

No trial has tested this combination. There is no published human study of AOD-9604 plus MOTS-c plus an incretin agonist, in any order or dose. Everything above is mechanistic reasoning across three separate literatures.

One failed its human test; one has never had one. AOD-9604's supportive data is mouse work from 2001, and its large human trial did not meet its primary weight-loss endpoint. MOTS-c's metabolic and muscle findings are mouse work from 2015 onward. Mouse metabolic studies translate to humans inconsistently — and in obesity pharmacology specifically, the failure rate from promising rodent data to human efficacy is high.

Mechanistic complementarity is not synergy. Non-overlapping targets mean the compounds are unlikely to be redundant. That is a different claim from them being additive, and a very different claim from them being greater than additive. Interactions can also be negative; nothing in the published record rules that out because nothing in the published record has looked.

The composition argument is inferential. We know incretin-driven weight loss includes fat-free mass. We do not have evidence that MOTS-c or AOD-9604 changes that in humans. Resistance training and adequate protein intake have far better support for preserving lean mass during weight loss than any peptide discussed here.

Regulatory and purity status differ sharply across the three. Tirzepatide is an approved drug. AOD-9604 and MOTS-c are research compounds, and AOD-9604 appears in anti-doping analytical literature — relevant for anyone in tested sport. See our notes on regulatory status and purity versus content.

Where Research Stands

For anyone designing research in this area, the evidence hierarchy is unusually lopsided and worth stating plainly: one approved drug class with multiple large randomised trials, and two research compounds whose supportive data is preclinical.

That asymmetry has a practical consequence for study design. Any observed effect in a three-compound combination would be dominated by the incretin, which makes the incretin-alone arm essential rather than optional — otherwise the design cannot distinguish a contribution from the other two compounds from the GLP working as it already does. Composition endpoints — DXA-measured fat and fat-free mass, not scale weight — are the measurements that would make such a study informative, since scale weight is the endpoint the GLP already answers.

Our evidence levels framework exists for exactly this kind of mixed picture, and negative results collects the trials that did not work — including in this drug space.

Peptide Mag does not publish dosing protocols for research compounds. The compounds here are discussed as research subjects, and the combination as an untested hypothesis.

References

  1. Heffernan M, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PubMed
  2. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed
  3. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
  4. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed
  5. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-associated manner. Free Radic Biol Med. 2026;246:682-696. PubMed
  6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
  7. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
  8. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
  9. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026;179(7):996-1013. PubMed
  10. Weighing the risk of GLP-1 treatment in older adults: should we be concerned about sarcopenic obesity? J Nutr Health Aging. 2025;29(10):100652. PubMed
  11. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: AOD-9604 (free base and acetate) assessment. 2024. Reviewed in our AOD-9604 guide